Keros Therapeutics Inc Reports Q3 2026 Earnings: GAAP EPS of $0. ...
Revenue From Takeda License Drives Quarterly Profitability as Pipeline Advances Related Stocks: KROS ,
Revenue From Takeda License Drives Quarterly Profitability as Pipeline Advances Related Stocks: KROS ,